Generics increase competition: study

Share this article:
A new study funded by PhRMA says the increasing use of authorized generics by drug companies has not led to delays in generic entry into the marketplace. “This study and others show that authorized generics are increasing competition and helping lower prescription drug prices for patients, not harming competition,” said PhRMA VP, policy and research, Lori Reilly. “As a result, proposals to restrict authorized generics would reduce consumer savings.”

The study by an MIT professor and Analysis Group researchers reportedly confirmed that the  increase in generics had not reduced incentives to challenge brand name patents.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.